NUCALA Market Size, Insight, and Forecast to 2032

This report provides comprehensive insights about NUCALA for Asthma in the seven major markets. A detailed picture of the NUCALA for Asthma in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2019-2032 is provided in this report along with a detailed description of the NUCALA for Asthma.

The report provides insights about mechanism of action, dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the NUCALA market forecast analysis for Asthma in the 7MM, SWOT, analysts’ views, comprehensive overview of market competitors, and brief about other emerging therapies in Asthma.

Drug Summary

NUCALA (Mepolizumab) is the first-in-class monoclonal antibody that targets IL-5, developed by GlaxoSmithKline. It prevents IL-5 from binding to its receptor on eosinophils’ surface, reducing blood eosinophils without completely depleting them. NUCALA is indicated for the add-on maintenance treatment of adult and pediatric patients aged 6 and older with severe asthma and an eosinophilic phenotype.

NUCALA is not indicated for the relief of acute bronchospasm or status asthmaticus.

Dosage and administration

For adults and adolescents aged 12 and older: The recommended dosage of NUCALA in adults and adolescents aged 12 and older is 100 mg once every 4 weeks by SC injection into the upper arm, thigh, or abdomen.

For pediatric patients aged 6-11: The recommended dosage of NUCALA for injection in pediatric patients aged 6-11 is 40 mg administered once every 4 weeks by SC injection into the upper arm, thigh, or abdomen.

Mechanism of action

Mepolizumab is an IL-5 antagonist (IgG1 kappa). IL-5 is the major cytokine responsible for the growth and differentiation, recruitment, activation, and survival of eosinophils. Mepolizumab binds to IL-5 with a dissociation constant of 100 pM, inhibiting the bioactivity of IL-5 by blocking its binding to the alpha chain of the IL-5 receptor complex expressed on the eosinophil cell surface. 

Scope of the Report

The report provides insights into:

• A comprehensive product overview including the NUCALA description, mechanism of action, dosage and administration, research and development activities in Asthma.
• Elaborated details on NUCALA regulatory milestones and other development activities have been provided in this report.
• The report also highlights the NUCALA research and development activities in Asthma across the United States, Europe, and Japan.
• The report also covers the patents information with expiry timeline around NUCALA.
• The report contains forecasted sales of NUCALA for Asthma till 2032.
• Comprehensive coverage of the late-stage emerging therapies for Asthma.
• The report also features the SWOT analysis with analyst views for NUCALA in Asthma.

Methodology

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by the team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

NUCALA Analytical Perspective

In-depth NUCALA Market Assessment

This report provides a detailed market assessment of NUCALA for Asthma in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides forecasted sales data from 2024 to 2032.

NUCALA Clinical Assessment

The report provides the clinical trials information of NUCALA for Asthma covering trial interventions, trial conditions, trial status, start and completion dates.

Report Highlights

• In the coming years, the market scenario for Asthma is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
• The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence NUCALA dominance.
• Other emerging products for Asthma are expected to give tough market competition to NUCALA and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of NUCALA in Asthma.
• This in-depth analysis of the forecasted sales data of NUCALA from 2024 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the NUCALA in Asthma.

Key Questions Answered

• What is the product type, route of administration and mechanism of action of NUCALA?
• What is the clinical trial status of the study related to NUCALA in Asthma and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the NUCALA development?
• What are the key designations that have been granted to NUCALA for Asthma?
• What is the forecasted market scenario of NUCALA for Asthma?
• What are the forecasted sales of NUCALA in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain) and the United Kingdom, and Japan?
• What are the other emerging products available and how are these giving competition to NUCALA for Asthma?
• Which are the late-stage emerging therapies under development for the treatment of Asthma?

This product will be delivered within 2 business days.